Pfizer reaffirms strong buy with raised guidance and attractive valuation amid pipeline growth.
Pfizer remains a strong buy as it reaffirms and raises its guidance, driven by operational growth of acquired assets at 18%. The company's robust pipeline, especially in obesity treatment and Vyndamax, supports growth beyond the 2028 loss of exclusiv...
